Suzhou GenHouse Pharmaceutical

GenHouse Pharmaceutical is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to developing innovative small molecule therapeutics for oncology. The company utilizes a proprietary structure-based drug discovery platform to target key drivers in the RAS/MAPK, Hippo, and other oncogenic signaling pathways. Its most advanced candidate, the KRAS G12C inhibitor fulzerasib (GFH925), has demonstrated significant clinical efficacy and is being developed in collaboration with Innovent Biologics. GenHouse also maintains a strategic global partnership with Merck KGaA for its SHP2 inhibitor program, GFH018. With a robust pipeline spanning from discovery to late-stage clinical trials, the company aims to address high unmet medical needs in solid tumors and hematological malignancies.